Trials / Conditions / Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia (CMML)

22 registered clinical trials studyying Chronic Myelomonocytic Leukemia (CMML) — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT NCT07302776	Stanford University	Phase 1
Recruiting	Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Thera NCT07128381	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Not Yet Recruiting	The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes NCT07113730	Peking University People's Hospital	—
Recruiting	A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxi NCT06859424	Center for International Blood and Marrow Transplant Research	Phase 2
Recruiting	A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias NCT06994676	Crossbow Therapeutics, Inc.	Phase 1
Recruiting	A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) NCT06950034	Solu Therapeutics, Inc	Phase 1
Terminated	A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS NCT06563804	Servier Bio-Innovation LLC	Phase 1 / Phase 2
Completed	A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R NCT05665530	Prelude Therapeutics	Phase 1
Completed	Pharmacokinetics, Tolerability and Safety of NEX-18a NCT05048498	Nanexa AB	Phase 1
Active Not Recruiting	Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations NCT04409639	University of Utah	Phase 2
Active Not Recruiting	Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations NCT04603001	Eli Lilly and Company	Phase 1
Withdrawn	SNS-301 Monotherapy in High Risk MDS and CMML NCT04217720	Sensei Biotherapeutics, Inc.	Phase 2
Terminated	Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML NCT03922100	Nerviano Medical Sciences	Phase 1 / Phase 2
Active Not Recruiting	Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MD NCT03613532	Jacqueline Garcia, MD	Phase 1
Terminated	Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome NCT02749708	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1
Completed	Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) NCT02546284	Humanigen, Inc.	Phase 1
Terminated	Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL NCT02147873	TetraLogic Pharmaceuticals	Phase 2
Completed	Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) NCT01842646	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Completed	Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) NCT01736683	Merck Sharp & Dohme LLC	Phase 2
Completed	A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS NCT01613976	Novartis Pharmaceuticals	Phase 1
Completed	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, NCT00528983	Celgene	Phase 1
Terminated	Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia NCT00664677	Erimos Pharmaceuticals	Phase 1